In Brief: ChemTrak
This article was originally published in The Gray Sheet
Executive Summary
ChemTrak: Reacquires from Astra Merck exclusive U.S. marketing rights to its Hp Chek rapid whole blood H. pylori test. Astra Merck, which will pay ChemTrak $2.4 mil. to return the rights, retains an option to obtain non-exclusive distribution rights in the future. Astra Merck, which offers its Prilosec (omeprazole) drug for ulcer treatment, notes that "many more prescriptions for Prilosec are written to treat gastroesophageal reflux disease," and says it has decided to "focus on the core business." The test gained 510(k) clearance in June 1996 ("The Gray Sheet" July 8, 1996, In Brief)...